Member Info for Monkshood

I was asking about this last week. If the mutation in S1 is the one that was suggested then it is not new so I would think that they would have looked at this already. Changes in proteins other than in the spike protein can also affect pathogenicity.
It may also be that the Kent strain is spreading more for other reasons? Kent has a fully selective school system so the kids travel together by train and bus far more than in many other areas .

More about relative abundances and what can be seen in 'real' samples-
Note - if you are looking at tryptic digests by MS, it is often as much about peptides that are good for MS as the absolute abundance. (to do with the digestion, size, charge stability). They point out in this paper, S is large so more choice of peptides.
https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00664

On the S/N theme in the paper below-
Because structural proteins are generally more abundant in virus particles, they are probably most suitable for MS-based detection, which can be seen in the SARS-CoV-2 nucleocapsid protein as the favored target for detection.(8,9,12)
They also highlight a peptide-ADETQALPQR- from the N protein as always being seen, which is what I mean by certain peptides make particularly good prototypic markers.

https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00674

Not sure if this has been posted before but it was new to me.

It does confirm what I thought about the using N vers S proteins-
'The N protein, being the most abundant protein in the virion, is the best candidate for mass-spectrometric detection of the infection, and so its detection is expected. '

They use a tryptic digest in the protocol, I am not sure a this would work for a high throughput screen (takes 1hr and can have problems ).
The kit used for the paper was research level equipment. The type of MS (nano LCMS/MS ) would not be suitable for screening (nano LC is tricky- try spotting a solvent leak @400nl/min-when a small droplet is approx 20ul ).
However if you want sensitivity -
'For example the use of PRM approaches on triple–quadrupole mass spectrometers based on the peptides identified in this study may allow us to go below the sensitivity of RT-qPCR, whereas the application of immunoprecipitation methods with subsequent MALDI analysis or even MALDI detection of viral proteins directly on the immobilized antibodies (iMALDI) will allow us to shorten the processing times to as low as 1 h.'

https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00412

Apologies - just realised I missed yesterdays thread....
Still no harm in flagging it again!

FDA approval-
Vectura Group plc (LSE: VEC) ("Vectura"), an industry-leading specialist inhalation CDMO, today announces that its partner Hikma Pharmaceuticals has launched its generic version of GlaxoSmithKline's Advair Diskus®1 (fluticasone propionate and salmeterol inhalation powder), 100mcg/50mcg and 250mcg/50mcg doses, in the US. The launch of the product follows approval by the US Food and Drug Administration (FDA)

I am sure it is possible to manipulate, but most are not first-time reviewers so I would be surprised if that were the case.

I saw an add in The Times at the w/e, may have caused a surge being delivered this week.

Tom, Which bit of this application note is your 'assay', with or without a tryptic digest?
What is the rest of the protocol ?
What is the sensitivity?
So, yes you can buy a kit to do affinity pull downs, but we still do not know what a commercial assay for Sars Cov2 screening by MS will be. They have only ever shown the results for a recombinant S1 protein - not a 'proper' sample.
It may well turn out to be great, but we do not know yet.

Oak, there is no data for a BAMS test, we do not even know what the test involves.

Trust pilot reviews continue to be very positive, four weeks ago there were 22, now it is up to 68. I am not sure how accurately the number of reviews correlates with sales (especially as many will be, so far, untested Christmas presents), however at 20 ish reviews they had 200k sales, so 68 should be about a further 400k which is what they were predicting for sale of all 7000 units they had sourced.
They have not sold out on the website, but it is certainly all looking very positive.

Not a dopey question, but there is no way of knowing without any data.
Abcams ELISA’s have sensitivity better for N than S (note -this is the protein not the virus it’s self for which there is no data) probably main difference I can see here is that the N ELISA cannot distinguish Cov2 from Cov (but that does not seem to be the case for some other assays targeting N)

COVID-19 N-Protein ELISA Kit (ab274341) | Abcam
COVID-19 Spike Protein ELISA Kit (ab274342) | Abcam

Abbott and Biodot both target the N protein.... Sona is the only other one I have found targeting the S1....

The December quarter should be a good one for them. They should have more unhedged gold, so the average price received will be higher.
Not only did they have the strike and consequent roaster shut down in the September quarter the grades poor were at Syama, in particular the oxide, this should be much better this quarter as they use ore from Cashew. Mako should be up a bit as well as the reduction last quarter was due to scheduled planned shutdowns.
Going forward, if they can, as it looks like, keep the lower cost oxide stream going at Tabakoroni it will give them some time to get their debt down before any capex is need for going underground.
With the Bibiani sale there does seem to be a change in sentiment, a good quarter will help keep the momentum going. We will find out in early Jan….

I still have some (well quite a few) reservations about rsg, but agree it is cheap at this price. I was holding off until it was clear how they would fund going underground at Tabakoroni. They also seem to have pushed back on the start date for this, assumedly pressure to get debt under control first.
If we get some clarity over the tax situation and they hit their targets then it does have the potential to jump on the next quarterly in Jan (but I have thought that before ...)
I was surprised that we got to hear first, so hopefully the asx will push this up tonight.

This is for $105M, going forward, they have the potential to realise a further $188M from the Ravenswood sale. They have at least A$50M in equity stakes in exploration companies(Oklo/Orca/Loncor/Manas/Mali lithium), plus a joint exploration project with Toya which is due to report soon.
Net debt was $234M at the last update.
They will need about $90M for the Tabakoroni development (but not yet), this should be covered the the Bibiani sale and so eliminate the need for an equity raise.
The new power plant battery storage is due to be commissioned soon which should reduce costs on the sulphide circuit, this is where the ASIC has always been high so it could make a significant difference ( note- Aggreko get half of the value of the energy savings, not always clearly flagged by rsg…)

Hopefully they have been managing to sell gold for more than it costs to mine it this quarter, so I have decided to tentatively start a holding here again. On average I have done little better than break even on this in the past, hope to do a bit better this time!

Irons?? =virons

The only accurate test will be to also see if you can isolate viable irons from these samples as well.
Personally, I don't think that the deaths and pressure on hospital beds around the world comes from false positives, but perhaps all of the governments of all countries are working together in some giant conspiracy to sell PCR kits.....

Thanks -S1 : N501Y- This S protein AA change is not that new or unique (other changes may be)

https://nextstrain.org/groups/neherlab/ncov/S.N501?c=gt-S_501

Lets hope that this one does not affect binding of the Affimers. It is not a peptide they detect in the tryptic BAMS digests.
The Pfizer vaccine use the RBD of S1 (AA- 331 to 524), so there is the potential for this to be impacted but this has not been flagged like the mink one was , so hopefully not. (A cull of the Men of Kent, and Kentish Men on the cards??)

Awarded new business worth c.£2.2m by one of its key clients.
Even more importantly - annual recurring revenue generated by the client is expected to increase by approximately £0.5 million

Increase in profit by 10%, being no less than £3.3 million.
Continued to win many new customers around the world.
Sales of our new Cache product range will be approximately double their level of the first half last year.
In North America very encouraging progress has been made in our FDA test programme.
In India we expect to conclude distribution arrangements for our entire Duo product range before Christmas.

Thanks, I think that is the mink mutation - so not sure that it is the new one (reported to originate in Kent).
https://nextstrain.org/groups/neherlab/ncov/S.Y453F?c=country&f_region=Europe